- In January 2025, Sartorius AG, a global leader in laboratory equipment, announced the launch of its latest automated membrane chromatography system, designed to improve scalability and efficiency in biopharmaceutical manufacturing. The system integrates with Sartorius’ advanced bioreactor platforms, offering real-time monitoring of protein purification processes. This development aims to enhance high-throughput production of monoclonal antibodies and vaccines, contributing to the growing demand for biologics
- In December 2024, Merck KGaA introduced a new line of high-performance membrane chromatography columns that promise significant reductions in purification time and costs. These columns are designed specifically for viral vector production, catering to the booming gene therapy market. The new membranes enhance recovery rates and purity, allowing for faster production cycles while maintaining product quality
- In November 2024, Danaher Corporation showcased its latest advancements in membrane chromatography technology at the BioProcess International Conference. Their new offering integrates with automated systems, streamlining the entire purification process for biologics and reducing operational costs by up to 25%. This innovation is expected to support the increased demand for cell and gene therapies, making it easier for manufacturers to scale up production
- In October 2024, Pall Biotech announced the commercial availability of a new membrane chromatography solution specifically designed for large-scale purification of therapeutic proteins. The platform is equipped with enhanced performance characteristics, including higher flow rates and improved capacity, enabling faster processing of high-value biopharmaceuticals such as monoclonal antibodies and biosimilars. The solution also offers cost-effective scalability, making it an attractive choice for pharmaceutical manufacturers
